Every open market buy and sale of Candel Therapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are net sellers over the last 12 months: $3M bought and $3.6M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when CADL insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an CADL officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every CADL insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter TakCEO | Sale plan | 280,245 | $11.28 | $3.2M | 113,321 | Sep 11Form 4 |
| Aug 17, 2026 | Seshu TyagarajanChief Technology Officer | Sale plan | 7,000 | $12.00 | $84K | 76,865 | Aug 19Form 4 |
| Jun 29, 2026 | Francesca BaroneChief Scientific Officer | Sale plan | 23,447 | $10.06 | $236K | 77,362 | Jul 1Form 4 |
| Jun 29, 2026 | Seshu TyagarajanChief Technology Officer | Sale plan | 7,000 | $10.02 | $70K | 83,865 | Jul 1Form 4 |
| Feb 23, 2026 | Paul B ManningDirector | Buy | 550,458 | $5.45 | $3M | 2,763,527 | Feb 26Form 4 |
| Jul 28, 2025 | William Garrett NicholsChief Medical Officer | Sale plan | 937 | $6.98 | $7K | 52,493 | Jul 30Form 4 |
| Jun 30, 2025 | William Garrett NicholsChief Medical Officer | Sale plan | 781 | $5.04 | $4K | 52,493 | Jul 2Form 4 |
| Mar 19, 2025 | Paul Peter TakCEO | Sale plan | 26,172 | $8.77 | $230K | 225,740 | Mar 20Form 4 |
| Mar 18, 2025 | Francesca BaroneChief Scientific Officer | Sale plan | 32,146 | $8.76 | $282K | 96,527 | Mar 20Form 4 |
| Mar 18, 2025 | William Garrett NicholsChief Medical Officer | Sale plan | 45,316 | $8.76 | $397K | 52,493 | Mar 20Form 4 |
| Mar 17, 2025 | Charles SchochSee Remarks | Sale plan | 5,000 | $8.83 | $44K | 38,038 | Mar 19Form 4 |
| Mar 17, 2025 | Seshu TyagarajanChief Technology Officer | Sale plan | 31,278 | $8.82 | $276K | 85,512 | Mar 19Form 4 |
| Jan 15, 2025 | William Garrett NicholsChief Medical Officer | Sale | 10,428 | $7.23 | $75K | 79,320 | Jan 17Form 4 |
| Jan 15, 2025 | Paul Peter TakCEO | Sale | 21,704 | $7.23 | $157K | 251,912 | Jan 17Form 4 |
| Jan 15, 2025 | Charles SchochSee Remarks | Sale | 9,511 | $7.23 | $69K | 43,038 | Jan 17Form 4 |
CADL insider trading FAQ
Are CADL insiders buying or selling?
Insiders are net sellers over the last 12 months. 1 insiders bought $3M of CADL on the open market in 1 trades, and 3 sold $3.6M in 4 trades, 100% of that under pre-arranged trading plans.
When did an CADL insider last buy shares?
Paul B Manning (Director) bought 550,458 shares for $3M on Feb 23, 2026, reported on Feb 26, 2026.
When did an CADL insider last sell shares?
Paul Peter Tak (CEO) sold 280,245 shares for $3.2M on Sep 11, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
